Protein-Protein Interaction (PPI) Target - Drug Discovery Case Study

January, 2012

Ark Therapeutics and Domainex worked together to develop what are believed to be the first small molecule antagonists with nanomolar potencies for the neuropilin 1 (NRP1) receptor. This is considered to be a protein-protein interaction target of high potential in the treatment of cancer.

NRP1 is a receptor for vascular endothelial growth factor A165 (VEGF-A165) and the neuronal guidance molecule semaphorin 3A (SEMA3A)2 with key roles in vascular and neuronal development. In endothelial cells, NRP1 enhances the biological signals of VEGF-A mediated by binding to its receptor vascular endothelial growth factor 2 (VEGFR2).

NRP1 has also been implicated in tumour growth and angiogenesis.  Inhibition by a blocking antibody that prevents VEGF-A binding to NRP1, enhanced the antitumor effects of the inhibitory anti-VEGF-A antibody, bevacizumab in mouse xenograft models.  It is therefore believed that a small molecule inhibitor of NRP1 function would be desirable, but inhibitors of protein-protein interactions are not trivial to develop.

Domainex and Ark worked together successfully to develop inhibitors of this interaction, using a peptidomimetic approach. This work was published by Jarvis et al. in 2010 and Haiyan Jia et al. in 2014.

If you would like to discover more about our services, discuss specific research, or receive a proposal, please contact us or email enquiries@domainex.co.uk